Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 178

1.

Pin1 inhibition sensitizes chemotherapy in gastric cancer cells by targeting stem-cell like traits and multiple biomarkers.

Zhang ZZ, Yu WX, Zheng M, Liao XH, Wang JC, Yang DY, Lu WX, Wang L, Zhang S, Liu HK, Zhou XZ, Lu KP.

Mol Cancer Ther. 2019 Dec 26. pii: molcanther.0656.2019. doi: 10.1158/1535-7163.MCT-19-0656. [Epub ahead of print]

PMID:
31879364
2.

Targeting Pin1 by All-Trans Retinoic Acid (ATRA) Overcomes Tamoxifen Resistance in Breast Cancer via Multifactorial Mechanisms.

Huang S, Chen Y, Liang ZM, Li NN, Liu Y, Zhu Y, Liao D, Zhou XZ, Lu KP, Yao Y, Luo ML.

Front Cell Dev Biol. 2019 Dec 6;7:322. doi: 10.3389/fcell.2019.00322. eCollection 2019.

3.

Traumatic Brain Injury-related voiding dysfunction in mice is caused by damage to rostral pathways, altering inputs to the reflex pathways.

Albayram O, MacIver B, Mathai J, Verstegen A, Baxley S, Qiu C, Bell C, Caldarone BJ, Zhou XZ, Lu KP, Zeidel M.

Sci Rep. 2019 Jun 14;9(1):8646. doi: 10.1038/s41598-019-45234-8.

4.

Targeting PIN1 exerts potent antitumor activity in pancreatic ductal carcinoma via inhibiting tumor metastasis.

Chen L, Xu X, Wen X, Xu S, Wang L, Lu W, Jiang M, Huang J, Yang D, Wang J, Zheng M, Zhou XZ, Lu KP, Liu H.

Cancer Sci. 2019 Aug;110(8):2442-2455. doi: 10.1111/cas.14085. Epub 2019 Jun 25.

5.

Pin1 inhibition potently suppresses gastric cancer growth and blocks PI3K/AKT and Wnt/β-catenin oncogenic pathways.

Zhang Z, Yu W, Zheng M, Liao X, Wang J, Yang D, Lu W, Wang L, Zhang S, Liu H, Zhou XZ, Lu KP.

Mol Carcinog. 2019 Aug;58(8):1450-1464. doi: 10.1002/mc.23027. Epub 2019 Apr 26.

PMID:
31026381
6.

An IRAK1-PIN1 signalling axis drives intrinsic tumour resistance to radiation therapy.

Liu PH, Shah RB, Li Y, Arora A, Ung PM, Raman R, Gorbatenko A, Kozono S, Zhou XZ, Brechin V, Barbaro JM, Thompson R, White RM, Aguirre-Ghiso JA, Heymach JV, Lu KP, Silva JM, Panageas KS, Schlessinger A, Maki RG, Skinner HD, de Stanchina E, Sidi S.

Nat Cell Biol. 2019 Feb;21(2):203-213. doi: 10.1038/s41556-018-0260-7. Epub 2019 Jan 21.

7.

Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.

Liao WS, Ho Y, Lin YW, Naveen Raj E, Liu KK, Chen C, Zhou XZ, Lu KP, Chao JI.

Acta Biomater. 2019 Mar 1;86:395-405. doi: 10.1016/j.actbio.2019.01.025. Epub 2019 Jan 16.

PMID:
30660004
8.

SPOP Promotes Nanog Destruction to Suppress Stem Cell Traits and Prostate Cancer Progression.

Zhang J, Chen M, Zhu Y, Dai X, Dang F, Ren J, Ren S, Shulga YV, Beca F, Gan W, Wu F, Lin YM, Zhou X, DeCaprio JA, Beck AH, Lu KP, Huang J, Zhao C, Sun Y, Gao X, Pandolfi PP, Wei W.

Dev Cell. 2019 Feb 11;48(3):329-344.e5. doi: 10.1016/j.devcel.2018.11.035. Epub 2018 Dec 27.

9.

Pin1 inhibition reverses the acquired resistance of human hepatocellular carcinoma cells to Regorafenib via the Gli1/Snail/E-cadherin pathway.

Wang J, Zhang N, Han Q, Lu W, Wang L, Yang D, Zheng M, Zhang Z, Liu H, Lee TH, Zhou XZ, Lu KP.

Cancer Lett. 2019 Mar 1;444:82-93. doi: 10.1016/j.canlet.2018.12.010. Epub 2018 Dec 21.

PMID:
30583078
10.

Targeting Prion-like Cis Phosphorylated Tau Pathology in Neurodegenerative Diseases.

Albayram O, Angeli P, Bernstein E, Baxley S, Gao Z, Lu KP, Zhou XZ.

J Alzheimers Dis Parkinsonism. 2018;8(3). pii: 443. doi: 10.4172/2161-0460.1000443. Epub 2018 Jun 29.

11.

Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells.

Kozono S, Lin YM, Seo HS, Pinch B, Lian X, Qiu C, Herbert MK, Chen CH, Tan L, Gao ZJ, Massefski W, Doctor ZM, Jackson BP, Chen Y, Dhe-Paganon S, Lu KP, Zhou XZ.

Nat Commun. 2018 Aug 9;9(1):3069. doi: 10.1038/s41467-018-05402-2.

12.

Correction to: Pin1 inhibition exerts potent activity against acute myeloid leukemia through blocking multiple cancer-driving pathways.

Lian X, Lin YM, Kozono S, Herbert MK, Li X, Yuan X, Guo J, Guo Y, Tang M, Lin J, Huang Y, Wang B, Qiu C, Tsai CY, Xie J, Gao ZJ, Wu Y, Liu H, Zhou XZ, Lu KP, Chen Y.

J Hematol Oncol. 2018 Jul 11;11(1):94. doi: 10.1186/s13045-018-0634-0.

13.

Pin1 inhibition exerts potent activity against acute myeloid leukemia through blocking multiple cancer-driving pathways.

Lian X, Lin YM, Kozono S, Herbert MK, Li X, Yuan X, Guo J, Guo Y, Tang M, Lin J, Huang Y, Wang B, Qiu C, Tsai CY, Xie J, Gao ZJ, Wu Y, Liu H, Zhou XZ, Lu KP, Chen Y.

J Hematol Oncol. 2018 May 30;11(1):73. doi: 10.1186/s13045-018-0611-7. Erratum in: J Hematol Oncol. 2018 Jul 11;11(1):94.

14.

The IL-33-PIN1-IRAK-M axis is critical for type 2 immunity in IL-33-induced allergic airway inflammation.

Nechama M, Kwon J, Wei S, Kyi AT, Welner RS, Ben-Dov IZ, Arredouani MS, Asara JM, Chen CH, Tsai CY, Nelson KF, Kobayashi KS, Israel E, Zhou XZ, Nicholson LK, Lu KP.

Nat Commun. 2018 Apr 23;9(1):1603. doi: 10.1038/s41467-018-03886-6.

15.

Association of CYP3A4*1B genotype with Cyclosporin A pharmacokinetics in renal transplant recipients: A meta-analysis.

Wang CE, Lu KP, Chang Z, Guo ML, Qiao HL.

Gene. 2018 Jul 20;664:44-49. doi: 10.1016/j.gene.2018.04.043. Epub 2018 Apr 18.

PMID:
29678659
16.

Concussion, microvascular injury, and early tauopathy in young athletes after impact head injury and an impact concussion mouse model.

Tagge CA, Fisher AM, Minaeva OV, Gaudreau-Balderrama A, Moncaster JA, Zhang XL, Wojnarowicz MW, Casey N, Lu H, Kokiko-Cochran ON, Saman S, Ericsson M, Onos KD, Veksler R, Senatorov VV Jr, Kondo A, Zhou XZ, Miry O, Vose LR, Gopaul KR, Upreti C, Nowinski CJ, Cantu RC, Alvarez VE, Hildebrandt AM, Franz ES, Konrad J, Hamilton JA, Hua N, Tripodis Y, Anderson AT, Howell GR, Kaufer D, Hall GF, Lu KP, Ransohoff RM, Cleveland RO, Kowall NW, Stein TD, Lamb BT, Huber BR, Moss WC, Friedman A, Stanton PK, McKee AC, Goldstein LE.

Brain. 2018 Feb 1;141(2):422-458. doi: 10.1093/brain/awx350.

17.

A novel controlled release formulation of the Pin1 inhibitor ATRA to improve liver cancer therapy by simultaneously blocking multiple cancer pathways.

Yang D, Luo W, Wang J, Zheng M, Liao XH, Zhang N, Lu W, Wang L, Chen AZ, Wu WG, Liu H, Wang SB, Zhou XZ, Lu KP.

J Control Release. 2018 Jan 10;269:405-422. doi: 10.1016/j.jconrel.2017.11.031. Epub 2017 Nov 21.

18.

Cis P-tau is induced in clinical and preclinical brain injury and contributes to post-injury sequelae.

Albayram O, Kondo A, Mannix R, Smith C, Tsai CY, Li C, Herbert MK, Qiu J, Monuteaux M, Driver J, Yan S, Gormley W, Puccio AM, Okonkwo DO, Lucke-Wold B, Bailes J, Meehan W, Zeidel M, Lu KP, Zhou XZ.

Nat Commun. 2017 Oct 17;8(1):1000. doi: 10.1038/s41467-017-01068-4.

19.

Military Blast Injury and Chronic Neurodegeneration: Research Presentations from the 2015 International State-of-the-Science Meeting.

Agoston D, Arun P, Bellgowan P, Broglio S, Cantu R, Cook D, da Silva UO, Dickstein D, Elder G, Fudge E, Gandy S, Gill J, Glenn JF, Gupta RK, Hinds S, Hoffman S, Lattimore T, Lin A, Lu KP, Maroon J, Okonkwo D, Perl D, Robinson M, Rosen C, Smith D.

J Neurotrauma. 2017 Sep;34(S1):S6-S17. doi: 10.1089/neu.2017.5220.

20.

Association of cancer and Alzheimer's disease risk in a national cohort of veterans.

Frain L, Swanson D, Cho K, Gagnon D, Lu KP, Betensky RA, Driver J.

Alzheimers Dement. 2017 Dec;13(12):1364-1370. doi: 10.1016/j.jalz.2017.04.012. Epub 2017 Jul 12.

21.

Prolyl isomerase PIN1 regulates the stability, transcriptional activity and oncogenic potential of BRD4.

Hu X, Dong SH, Chen J, Zhou XZ, Chen R, Nair S, Lu KP, Chen LF.

Oncogene. 2017 Sep 7;36(36):5177-5188. doi: 10.1038/onc.2017.137. Epub 2017 May 8.

22.

Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma.

Zheng M, Xu H, Liao XH, Chen CP, Zhang AL, Lu W, Wang L, Yang D, Wang J, Liu H, Zhou XZ, Lu KP.

Oncotarget. 2017 May 2;8(18):29771-29784. doi: 10.18632/oncotarget.15967.

23.

MicroRNA-140-5p inhibits hepatocellular carcinoma by directly targeting the unique isomerase Pin1 to block multiple cancer-driving pathways.

Yan X, Zhu Z, Xu S, Yang LN, Liao XH, Zheng M, Yang D, Wang J, Chen D, Wang L, Liu X, Liu J, Chen RH, Zhou XZ, Lu KP, Liu H.

Sci Rep. 2017 Apr 6;7:45915. doi: 10.1038/srep45915.

24.

Chemical or genetic Pin1 inhibition exerts potent anticancer activity against hepatocellular carcinoma by blocking multiple cancer-driving pathways.

Liao XH, Zhang AL, Zheng M, Li MQ, Chen CP, Xu H, Chu QS, Yang D, Lu W, Tsai TF, Liu H, Zhou XZ, Lu KP.

Sci Rep. 2017 Mar 6;7:43639. doi: 10.1038/srep43639.

25.

Function and regulation of tau conformations in the development and treatment of traumatic brain injury and neurodegeneration.

Albayram O, Herbert MK, Kondo A, Tsai CY, Baxley S, Lian X, Hansen M, Zhou XZ, Lu KP.

Cell Biosci. 2016 Dec 5;6:59. doi: 10.1186/s13578-016-0124-4. eCollection 2016. Review.

26.

Pin1 Knockout Mice: A Model for the Study of Tau Pathology in Alzheimer's Disease.

Kondo A, Albayram O, Zhou XZ, Lu KP.

Methods Mol Biol. 2017;1523:415-425.

PMID:
27975268
27.

The Roles of the Unique Prolyl Isomerase Pin1 in Cancer-Related Viral and Bacterial Infections.

Wang J, Liao XH, Zheng M, Yang D, Zhou XZ, Liu H, Lu KP.

Curr Mol Med. 2016;16(9):793-802. doi: 10.2174/1566524016666161124103654. Review.

PMID:
27889995
28.

Neighboring phosphoSer-Pro motifs in the undefined domain of IRAK1 impart bivalent advantage for Pin1 binding.

Rogals MJ, Greenwood AI, Kwon J, Lu KP, Nicholson LK.

FEBS J. 2016 Dec;283(24):4528-4548. doi: 10.1111/febs.13943. Epub 2016 Nov 20.

29.

G Protein-coupled Receptor Kinase 2 (GRK2) Promotes Breast Tumorigenesis Through a HDAC6-Pin1 Axis.

Nogués L, Reglero C, Rivas V, Salcedo A, Lafarga V, Neves M, Ramos P, Mendiola M, Berjón A, Stamatakis K, Zhou XZ, Lu KP, Hardisson D, Mayor F Jr, Penela P.

EBioMedicine. 2016 Nov;13:132-145. doi: 10.1016/j.ebiom.2016.09.030. Epub 2016 Oct 1.

30.

Cyclic cis-Locked Phospho-Dipeptides Reduce Entry of AβPP into Amyloidogenic Processing Pathway.

Fisher CL, Resnick RJ, De S, Acevedo LA, Lu KP, Schroeder FC, Nicholson LK.

J Alzheimers Dis. 2017;55(1):391-410.

31.

Potential of the Antibody Against cis-Phosphorylated Tau in the Early Diagnosis, Treatment, and Prevention of Alzheimer Disease and Brain Injury.

Lu KP, Kondo A, Albayram O, Herbert MK, Liu H, Zhou XZ.

JAMA Neurol. 2016 Nov 1;73(11):1356-1362. doi: 10.1001/jamaneurol.2016.2027. Review.

PMID:
27654282
32.

The role of Pin1 in the development and treatment of cancer.

Min SH, Zhou XZ, Lu KP.

Arch Pharm Res. 2016 Dec;39(12):1609-1620. doi: 10.1007/s12272-016-0821-x. Epub 2016 Aug 29. Review.

PMID:
27572155
33.

Critical role of XBP1 in cancer signalling is regulated by PIN1.

Chae U, Park SJ, Kim B, Wei S, Min JS, Lee JH, Park SH, Lee AH, Lu KP, Lee DS, Min SH.

Biochem J. 2016 Sep 1;473(17):2603-10. doi: 10.1042/BCJ20160482. Epub 2016 Jun 22.

PMID:
27334111
34.

The isomerase PIN1 controls numerous cancer-driving pathways and is a unique drug target.

Zhou XZ, Lu KP.

Nat Rev Cancer. 2016 Jul;16(7):463-78. doi: 10.1038/nrc.2016.49. Epub 2016 Jun 3. Review.

PMID:
27256007
35.

ATR Plays a Direct Antiapoptotic Role at Mitochondria, which Is Regulated by Prolyl Isomerase Pin1.

Hilton BA, Li Z, Musich PR, Wang H, Cartwright BM, Serrano M, Zhou XZ, Lu KP, Zou Y.

Mol Cell. 2016 Feb 4;61(3):487. doi: 10.1016/j.molcel.2016.01.016. Epub 2016 Feb 4. No abstract available.

36.

Prolyl Isomerase Pin1 Regulates Axon Guidance by Stabilizing CRMP2A Selectively in Distal Axons.

Balastik M, Zhou XZ, Alberich-Jorda M, Weissova R, Žiak J, Pazyra-Murphy MF, Cosker KE, Machonova O, Kozmikova I, Chen CH, Pastorino L, Asara JM, Cole A, Sutherland C, Segal RA, Lu KP.

Cell Rep. 2015 Oct 27;13(4):812-828. doi: 10.1016/j.celrep.2015.09.026. Epub 2015 Oct 17.

37.

ATR Plays a Direct Antiapoptotic Role at Mitochondria, which Is Regulated by Prolyl Isomerase Pin1.

Hilton BA, Li Z, Musich PR, Wang H, Cartwright BM, Serrano M, Zhou XZ, Lu KP, Zou Y.

Mol Cell. 2015 Oct 1;60(1):35-46. doi: 10.1016/j.molcel.2015.08.008. Epub 2015 Sep 18.

38.

[Effect of Long-term Fertilizer Application on the Stability of Organic Carbon in Particle Size Fractions of a Paddy Soil in Zhejiang Province, China].

Mao XL, Lu KP, Sun T, Zhang XK, He LZ, Wang HL.

Huan Jing Ke Xue. 2015 May;36(5):1827-35. Chinese.

PMID:
26314136
39.

Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy.

Kondo A, Shahpasand K, Mannix R, Qiu J, Moncaster J, Chen CH, Yao Y, Lin YM, Driver JA, Sun Y, Wei S, Luo ML, Albayram O, Huang P, Rotenberg A, Ryo A, Goldstein LE, Pascual-Leone A, McKee AC, Meehan W, Zhou XZ, Lu KP.

Nature. 2015 Jul 23;523(7561):431-436. doi: 10.1038/nature14658. Epub 2015 Jul 15.

40.

Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer.

Wei S, Kozono S, Kats L, Nechama M, Li W, Guarnerio J, Luo M, You MH, Yao Y, Kondo A, Hu H, Bozkurt G, Moerke NJ, Cao S, Reschke M, Chen CH, Rego EM, Lo-Coco F, Cantley LC, Lee TH, Wu H, Zhang Y, Pandolfi PP, Zhou XZ, Lu KP.

Nat Med. 2015 May;21(5):457-66. doi: 10.1038/nm.3839. Epub 2015 Apr 13.

41.

The Rab2A GTPase promotes breast cancer stem cells and tumorigenesis via Erk signaling activation.

Luo ML, Gong C, Chen CH, Hu H, Huang P, Zheng M, Yao Y, Wei S, Wulf G, Lieberman J, Zhou XZ, Song E, Lu KP.

Cell Rep. 2015 Apr 7;11(1):111-24. doi: 10.1016/j.celrep.2015.03.002. Epub 2015 Mar 26.

42.

Lead accumulation and tolerance of Moso bamboo (Phyllostachys pubescens) seedlings: applications of phytoremediation.

Liu D, Li S, Islam E, Chen JR, Wu JS, Ye ZQ, Peng DL, Yan WB, Lu KP.

J Zhejiang Univ Sci B. 2015 Feb;16(2):123-30. doi: 10.1631/jzus.B1400107.

43.

Theileria parasites secrete a prolyl isomerase to maintain host leukocyte transformation.

Marsolier J, Perichon M, DeBarry JD, Villoutreix BO, Chluba J, Lopez T, Garrido C, Zhou XZ, Lu KP, Fritsch L, Ait-Si-Ali S, Mhadhbi M, Medjkane S, Weitzman JB.

Nature. 2015 Apr 16;520(7547):378-82. doi: 10.1038/nature14044. Epub 2015 Jan 26.

44.

Pin1 dysregulation helps to explain the inverse association between cancer and Alzheimer's disease.

Driver JA, Zhou XZ, Lu KP.

Biochim Biophys Acta. 2015 Oct;1850(10):2069-76. doi: 10.1016/j.bbagen.2014.12.025. Epub 2015 Jan 10. Review.

45.

Pin1 cysteine-113 oxidation inhibits its catalytic activity and cellular function in Alzheimer's disease.

Chen CH, Li W, Sultana R, You MH, Kondo A, Shahpasand K, Kim BM, Luo ML, Nechama M, Lin YM, Yao Y, Lee TH, Zhou XZ, Swomley AM, Butterfield DA, Zhang Y, Lu KP.

Neurobiol Dis. 2015 Apr;76:13-23. doi: 10.1016/j.nbd.2014.12.027. Epub 2015 Jan 6.

46.

Variants -250G/A and -514C/T in the LIPC gene are associated with hypertensive disorders of pregnancy in Chinese women.

Lin H, Yin Z, Yu XY, Lin N, Lin Y, Chen J, Chen YZ, Lu KP, Liu HK.

Genet Mol Res. 2014 Aug 7;13(3):6126-34. doi: 10.4238/2014.August.7.28.

47.

Prolyl isomerase Pin1 acts downstream of miR200c to promote cancer stem-like cell traits in breast cancer.

Luo ML, Gong C, Chen CH, Lee DY, Hu H, Huang P, Yao Y, Guo W, Reinhardt F, Wulf G, Lieberman J, Zhou XZ, Song E, Lu KP.

Cancer Res. 2014 Jul 1;74(13):3603-16. doi: 10.1158/0008-5472.CAN-13-2785. Epub 2014 May 1.

48.

The prolyl isomerase Pin1 regulates hypoxia-inducible transcription factor (HIF) activity.

Jalouli M, Déry MA, Lafleur VN, Lamalice L, Zhou XZ, Lu KP, Richard DE.

Cell Signal. 2014 Aug;26(8):1649-56. doi: 10.1016/j.cellsig.2014.04.005. Epub 2014 Apr 12.

PMID:
24726894
49.

Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus.

Liu P, Begley M, Michowski W, Inuzuka H, Ginzberg M, Gao D, Tsou P, Gan W, Papa A, Kim BM, Wan L, Singh A, Zhai B, Yuan M, Wang Z, Gygi SP, Lee TH, Lu KP, Toker A, Pandolfi PP, Asara JM, Kirschner MW, Sicinski P, Cantley L, Wei W.

Nature. 2014 Apr 24;508(7497):541-5. doi: 10.1038/nature13079. Epub 2014 Mar 9.

50.

Supplemental Content

Support Center